In a recent trial, adjuvant treatment with sunitinib significantly prolonged disease-free survival compared to placebo. This positive result is muted by the rate of side effects and overtreatment, raising the question of proper patient and agent selection in the adjuvant setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2016.10.023 | DOI Listing |
Publication Analysis
Top Keywords
adjuvant treatment
8
treatment high-risk
4
high-risk renal
4
renal cell
4
cell carcinoma
4
carcinoma leaving
4
leaving desert?
4
desert? trial
4
trial adjuvant
4
treatment sunitinib
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!